

Criminal Division

September 16, 2019

Leslie I. Ballin Ballin Ballin & Fishman 200 Jefferson Ave., Ste. 1250 Memphis, TN 38103 (901) 525 – 6278 lballin@bbfpc.com Manubir S. Arora Arora & Lascala 75 West Wieuca Road NE Atlanta, GA 30342 (404) 881 - 8866 manny@mannyarora.com

RE: United States v. Petway, et al. CR. No. 19-cr-10041-JDB

Dear Counsel:

Pursuant to Federal Rule of Criminal Procedure 16(a)(1)(G) and Federal Rules of Evidence 702, 703, and 705, the United States hereby provides notice that it may call Dr. Carl Christensen and Dr. John R. Schneider, in its case in chief.

You have previously received in discovery Dr. Christensen's February 10, 2019, file review and related documentation. The government anticipates that Dr. Christensen will testify regarding professional practice and the contents of his review.

The government anticipates that Dr. John R. Schneider, Medical Director and President of Comprehensive Pain & Neurology Center, PLLC, in Murfreesboro, Tennessee, will testify regarding medical standards for treating patients with opioids in Tennessee. If Dr. Schneider testifies at trial, he may testify regarding the facts set forth in Paragraphs 3 through 14 of the indictment, including the CDC guidelines, FDA warnings, and guidance provided to medical professionals in Tennessee.

Respectfully,

s/Jillian Willis
Jillian Willis
Trial Attorney
U.S. Department of Justice

Criminal Division, Fraud Section